Evaluation of Mild Leukocytosis with Erythrocytosis in a 54-Year-Old Male
This patient meets WHO 2016 diagnostic criteria for polycythemia vera (PV) and requires immediate JAK2 mutation testing, bone marrow biopsy, and initiation of therapeutic phlebotomy with aspirin to reduce thrombotic risk. 1
Diagnostic Approach
Immediate Recognition of Polycythemia Vera Criteria
This patient's laboratory values fulfill major diagnostic criteria for PV:
- Hemoglobin 17.9 g/dL exceeds the WHO 2016 threshold of >16.5 g/dL for men 1
- Hematocrit 52.9% exceeds the diagnostic threshold of >49% for men 1
- The leukocytosis (WBC 11.4) with neutrophilia (8014) is a common presenting feature, occurring in 49% of PV patients 2
Essential Diagnostic Testing
Order JAK2 mutation testing immediately, as >95% of PV patients harbor JAK2 variants (typically JAK2V617F), which distinguishes PV from secondary erythrocytosis causes like smoking or sleep apnea. 2
Additional required workup includes:
- Bone marrow biopsy to assess for age-adjusted hypercellularity with trilineage myeloproliferation and pleomorphic mature megakaryocytes 1
- Serum erythropoietin level (expected to be subnormal in PV) 1
- Peripheral blood smear examination to evaluate cell morphology and exclude other myeloproliferative neoplasms 3
Critical Differential Considerations
The neutrophilia (8014/μL) in this context is concerning for PV-associated leukocytosis rather than a reactive process, as neutrophilic leukocytosis at PV diagnosis is associated with increased thrombotic risk and more aggressive disease. 4
Exclude secondary causes of erythrocytosis:
- Tobacco smoking history 2
- Sleep apnea 2
- Chronic hypoxic conditions
- Renal pathology or erythropoietin-secreting tumors
A critical pitfall: Some PV patients present with normal hemoglobin/hematocrit ("masked PV") due to blood dilution or concurrent blood loss, but this patient's elevated values make overt PV more likely. 5
Risk Stratification for Thrombosis
This 54-year-old patient requires assessment for high-risk features:
- Age ≥60 years (this patient is 54, so intermediate risk) 2
- Prior thrombotic events (arterial thrombosis occurs in 16% at diagnosis, venous in 7%, including unusual sites like splanchnic veins) 2
- The presence of leukocytosis itself is an adverse prognostic factor associated with recurrent thrombosis 4
Immediate Management
Therapeutic Interventions
All PV patients require two foundational therapies regardless of risk category:
Therapeutic phlebotomy with a target hematocrit <45%, as the CYTO-PV trial established superiority of this goal for reducing thrombotic events 6, 2
Low-dose aspirin (if no contraindications) to reduce arterial and venous thrombosis risk 2
Cytoreductive Therapy Consideration
For patients aged ≥60 years or with prior thrombosis, cytoreductive therapy with hydroxyurea or interferon is recommended to lower thrombosis risk. 2
This 54-year-old patient falls into an intermediate category, but cytoreductive therapy should be strongly considered if:
- Persistent symptoms develop (pruritus occurs in 33%, erythromelalgia in 5.3%) 2
- Platelet count rises to thrombocytotic levels (thrombocytosis occurs in 53% of PV patients) 2
- Splenomegaly develops (present in 36% of patients) 2
Monitoring for Complications
Screen for acquired von Willebrand disease if platelet count reaches ≥1000 × 10⁹/L, as this creates paradoxical bleeding risk. 2
Long-term surveillance is essential, as 12.7% of PV patients develop myelofibrosis and 6.8% develop acute myeloid leukemia, with median survival ranging 14.1-27.6 years from diagnosis. 2
Key Pitfall to Avoid
Do not dismiss this as reactive leukocytosis simply because the WBC is only mildly elevated at 11.4—the combination with marked erythrocytosis strongly suggests myeloproliferative disease rather than infection or inflammation. 7, 3 Reactive processes typically show toxic granulation and left shift on peripheral smear, which should be absent in PV. 3